Kata Bölcskei. University of Pécs Department of Pharmacology and Pharmacotherapy. Clinical trials
|
|
- Mary Murphy
- 3 years ago
- Views:
Transcription
1 Clinical trials Kata Bölcskei University of Pécs Department of Pharmacology and Pharmacotherapy Clinical trials definition (ICH-GCP): Any investigation in human subjects intended to discover or verify the clinical, pharmacological and/or other pharmacodynamic effects of an investigational product(s), and/or to identify any adverse reactions to an investigational product(s), and/or to study absorption, distribution, metabolism, and excretion of an investigational product(s) with the object of ascertaining its safety and/or efficacy. 1
2 Ethical Principles for Medical Research Involving Human Subjects World Medical Association Declaration Of Helsinki - the investigators must protect the life, health, dignity, integrity, right to selfdetermination, privacy, and confidentiality of personal information of research subjects - the well-being of the individual research subject must take precedence over all other interests - participation of subjects must be voluntary after they were adequately informed about the aims, the procedures and potential benefits and risks of the study - subjects have the right to refuse to participate in the study or to withdraw consent to participate at any time without reprisal - research must conform to generally accepted scientific principles and can be conducted only by individuals with the appropriate scientific training and qualifications - research must immediately stop a study when the risks are found to outweigh the potential benefits - The research protocol must be submitted for consideration, comment, guidance and approval to a research ethics committee before the study begins [ ] independent of the researcher, the sponsor and any other undue influence - research on vulnerable population (e.g. minors, disabled): can only be performed if it is intended to promote the health of the population represented by the potential subject - informed consent must be asked from the legally authorized representative Legal regulation of clinical trials 35/2005. (VIII. 26.) Ministry of Health Regulation: on clinical trials of investigational new medical products for human use and the application of Good Clinical Practice (GCP) standards 235/2009. (X. 20.) Government Regulation: on the authorization process of medical research on humans, of clinical trials of new medicinal products or new medical devices 2
3 Requirements of clinical trial application - evidence of non-clinical efficacy and safety of the investigational drug (+ clinical efficacy and safety it is not the first clinical trial with the drug!) - evidence of appropriate chemical and pharmaceutical quality of the product - preparation of trial protocol, patient information and informed consent forms with regard to ethical and scientific standards - selection of trial site and principal investigator preparation of required documents application Process of authorization INDEPENDENT ETHICAL COMMITTEE (in HU: Medical Research Council Ethics Committee for Clinical Pharmacology) protocol patient information sheets informed consent forms investigators CVs trial site risk/benefit evaluation positive or negative opinion if + NATIONAL MEDICINES AGENCY (National Competent Authority, in HU: National Institute of Pharmacy) protocol non-clinical (and clinical safety anc efficacy data) pharmaceutical qualitiy of the investigational drug risk/benefit evaluation if + clinical trial authorization 3
4 Randomized controlled trial (RCT) - the most reliable study type of evidence-based medicine - an interventional trial: investigators apply a drug or other intervention to assess its safety and efficacy - controlled: the effects of the investigational drug is compared to a control group receiving placebo treatment or standard therapy (active control/comparator) - randomized: trial subjects are randomly allocated in one of the treatment groups - statistical methods are used to compare the outcome between the two groups Types of RCT trial designs based on treatment masking/blinding: open,open-label: both investigators and subjects know single-blind: only investigators know double-blind: neither of them know based on the type of control groups: placebo control active control - double-dummy: special case, when the investigational drug and the comparator drug have different appearance, subjects receive 1 investigational + 1 placebo OR 1 placebo + 1 comparator 4
5 Types of RCT trial designs three-armed comparison: investigational drug, placebo control, active control factorial design: if a combination of treatments (or other factors) is investigated, treatment groups are formed for all the possible combinations (e.g. 2 factors 4 groups) Types of RCT trial designs based on the purpose of comparison: - has to be determined in the protocol prior to the trial - different statistical analysis is used superiority trial: better than placebo or active control non-inferiority trial: not worse than active control equivalence: equal to active control bioequivalence study: comparison of the plasma concentration-time curves of a generic compound with the original 5
6 Types of RCT trial designs based on the sequence of the study: parallel design: subjects only receive one treatment, either investigational or control cross-over design: subjects receive both treatments one after the other, in different order (after a wash-out period) based on the site(s) of investigation: monocentric multicentric multinational Ethical problems of RCTs physicians are ethically obliged to do no harm, to apply the best proven treatment a randomized trial can violate this ethical principle because they do not know if the investigational treatment has a beneficial effect at all, nor if it is better than the best current treatment Two possible solutions to the ethical dilemma: uncertainty principle : the physician does not know which treatment is better, all patients have an equal chance of benefit or risk equiactivity principle : the physician considers both treatments equal 6
7 Ethical problems of RCTs Is it ethical to compare to placebo? Declaration of Helsinki 6th Revision (2008) The use of placebo, or no treatment, is acceptable in studies where no current proven intervention exists; or where for compelling and scientifically sound methodological reasons the use of placebo is necessary to determine the efficacy or safety of an intervention and the patients who receive placebo or no treatment will not be subject to any risk of serious or irreversible harm. Extreme care must be taken to avoid abuse of this option. Ethical problems of RCTs Is it ethical to compare to placebo? the use of placebo must be justified in the protocol: - patients must not suffer irreversible damage from participating in the study: placebo must not be used in severe, life-threatening diseases or lengthy trials - if placebo-treated patients condition significantly deteriorates, they must be withdrawn from the trial and given standard treatment another possibility: add-on treatment: investigational drug or placebo is combined with standard-of-care treatment 7
8 Phase 0 Studies: Exploratory human pharmacology new approach, optional study microdosing OR single subtherapeutic doses extending up to therapeutic range the only purpose is to study human pharmacology of the drug, NOT SUITABLE for assessing safety or efficacy can be authorized with less available preclinical toxicity data methods: pharmacokinetic parameters: high-sensitivity analytical methods pharmacodynamic actions: PET study: receptor binding in target tissue(s) Phase I clinical trials: human pharmacology studies purpose: investigation of TOLERABILITY, PHARMACOKINETICS and (if possible) PHARMACODYNAMICS subjects: healthy volunteers, generally male, years EXCEPT if the drug can potentially cause lasting health damage e.g. anti-tumor agents phase I/II study on patients definition of healthy : does not suffer from illness which could influence pharmacokinetics, pharmaco-dynamics or toxicity of the investigational drug 8
9 Phase I clinical trials: human pharmacology studies gender: women can be included but only if appropriate contraceptive methods are used! number of subjects: generally trial site: specialized Phase I trial units with ICU and laboratory support principal investigator: a specialist in Clinical Pharmacology Phase I trial designs randomized, placebo-controlled, SINGLE-blind: in case of emergency it is important that investigators know which subject was given the drug I/a study: acute tolerability: single, escalating dosing I/b study: repeated dose for 1 or 2 weeks - determine maximum tolerated dose (MTD) - pharmacokinetic parameters (C max, t max, T 1/2, AUC) under various conditions (fasting, food interaction, time of the day etc.) 9
10 Phase I trial designs selection of STARTING DOSE: various recommendations are available to calculate a maximum safe starting dose from preclinical animal toxicity data e.g. animal NOAEL (no observed adverse effect level) converted to human dose/divided by a safety factor (min. 10, but can be a lot higher depending on the severity of potential toxicity, novelty of the therapeutic class etc.) selection of DOSE ESCALATION: arithmetic: 1n, 2n, 3n, logarithmic: 1n, 2n, 4n, Fibonacci: 1n, 2n, 3n, 5n, 8n,modified Fibonacci: 1n, 2n, 3n, 5n, 7n, 9n, 12n Phase I study protocol considerations - start only on few subjects at a time, in case severe intolerance occurs - dose limiting toxicity: laboratory abnormalities or any sign or symptom of vital organ dysfunction (pulse/rr/ecg changes, nausea, vomiting, dizziness, headache etc. ) - include wash-out periods between dose escalations - timing of blood tests: more frequently around the expected C max, continue until 80% of AUC is included 10
11 Phase II clinical trials: therapeutic exploratory studies purpose: exploration of THERAPEUTIC EFFECT on patients ( pharmacodynamic action!), Proof of Concept provide basis for larger, confirmatory studies (dose selection, endpoint selection) monitor SAFETY in patients subjects: volunteer patients, years inclusion/exclusion criteria are generally strict in order to have a homogeneous group of patients trial site: hospital ward having the necessary equipment to perform procedures of the trial principal investigator: a specialist in the area of the intended indication AND in Clinical Pharmacology OR certified GCP training Clinical trial endpoints clinical endpoints are the measures of therapeutic response: clinically meaningful= directly measure the progression of the disease: how the patient FEELS, FUNCTIONS or SURVIVES - must be defined in the protocol prior to the study HIERARCHY of endpoints ( hardness, reliability) survival > definitive event (e.g. myocardial infarction) > laboratory values > CT, MRI scans > measurement of vital parameters > complex scoring of symptoms > VAS (visual analog scale) > QoL (Quality of Life) questionnaire 11
12 Clinical trial endpoints PRIMARY: the main question of the study e.g. does the treatment improve survival, improve patient s symptoms etc. usually only ONE primary endpoint SECONDARY: can be VARIOUS: additional variables measuring the main objective adverse effect profile additional information on the disease s impact, the patient s well-being e.g. physical activitiy, days of inabililty/hospitalization Clinical trial endpoints BIOMARKER: any measurable parameter which occurs in correlation with a pathological process and has diagnostic or prognostic value SURROGATE endpoints: a biomarker that does not directly measure the therapeutic response but it is in correlation with it - validated surrogate endpoints can be used as PRIMARY endpoints to get approval e.g. blood pressure myocardial infarction, stroke blood glucose complications of diabetes bone density osteoporotic bone fracture 12
13 Clinical trial endpoints - examples CANCER overall survival, progression-free survival CARDIOVASCULAR DISEASE number of cardiovascular events (myocardial infarction, stroke) RESPIRATORY COPD respiratory function (FEV 1 ), severity of dyspnea DEPRESSION Hamilton depression rating scale PAIN visual analog scale Phase II clinical trials: therapeutic exploratory studies II/a study: pilot study on a small number of patients, can be an openlabel study without control group exploration of dose-response relationship by flexible dosing might need to rely on a surrogate endpoint II/b study: randomized, double-blind, placebo- or active control or add-on trial verify therapeutic response, preferably with the same endpoints intended to use in Phase III dose-response relationship selection optimal dosing for Phase III trials of 13
14 Phase II is important go/no go decision point: Phase III is lengthy and very expensive! - if the drug was proven safe but not effective enough in the studied disease, another phase II trial can be started in a new indication Phase III clinical trials: therapeutic confirmatory studies purpose: confirmation of THERAPEUTIC EFFECT on a larger, more diverse population of patients also called Proof of Principle, pivotal efficacy studies explore less frequent adverse effects, drug interactions subjects: volunteer patients inclusion/exclusion criteria are less strict: elderly and children, people with different severity of the disease, people suffering from other diseases can be included subgroups can be later analyzed separately number of subjects: 1000<, depending on the prevalence of the disease 14
15 Phase III clinical trials: therapeutic confirmatory studies duration of the study: if a chronic disease is studied, at least 6 months, but can be years trial site: a multicenter, multinational trial the site can be a hospital ward or even a policlinic: but patients are not hospitalized, only make periodical visits for check-ups principal investigator: a specialist in the area of the intended indication, with GCP training Phase III clinical trials: therapeutic confirmatory studies trial design: randomized, doble-blind, placebo- or active control, or add-on trial dosing: preferably one dose which was selected in Phase II/b trials the formulation of the investigational drug must the the final form which is intended to be marketed 15
16 Phase III clinical trials: therapeutic confirmatory studies Statistical analysis due to the long duration of the trial, a high percentage of patients might not finish the study Intention-to-treat analysis: each subject is included whether they finished the trial or not Per protocol analysis: only subjects who completed the trial are included Phase IV clinical trials: post-approval studies the purpose is to gather more information on the drug: - to optimalize its use, analyze risk/benefit ratio - explore very rare adverse effects - compare it to other treatments can include randomized, open or double-blind studies (e.g. comparison to a competitor s drug) non-interventional studies: patients are only subjects to tests which are included in routine check-ups in Hungary: NOT considered as phase IV studies, but still need authorization! 16
17 Bioequivalence studies purpose: to compare plasma concentration-time curves of a generic drug to the original generics contain the same compound but the formulation might be different they are required to prove equivalence in order to market their product referring to the originator s clinical trial results bioequivalence: if plasma concentration-time curves are not significantly different, the two drugs are considered equally effective Bioequivalence studies subjects and trial site: similar to Phase I trials healthy, male volunteers OR patients number: 18, 24 or 36 tested at a Phase I Unit design: - usually a two-period, cross-over design, with a wash-out period of min. 5xT 1/2 - parallel, multiple period design if the compound has a long half-life or variable pharmacokinetics 17
18 dosing: Bioequivalence studies single dose is usually enough multiple dose steady-state: if PK parameters change with dose or time course of the study: all the factors which could influence absorption are standardized! e.g. GI motility (transit time ) absorption GI blood flow absorption GI secretions (local concentration ) absorption standard food and drinks, physical activity, body position is regulated blood samples are taken at exact time points drug concentration measurement Bioequivalence studies The main pharmacokinetic parameters C max, t max, AUC t (until last blood sample) and extrapolated AUC are determined AUC t must be at least 80% of AUC Statistical comparison: the two drugs are bioequivalent if the confidence interval of 90% of C maxgen /C maxorig and AUC Gen /AUC Orig are between 0.8 and 1.25 in the case of narrow therpeutic index drugs it can be stricter ( ), while in the case of drugs showing large variability of PK parameters the criteria can be more permissive (0,75-1,33) 18
Sheffield Kidney Institute. Planning a Clinical Trial
Planning a Clinical Trial Clinical Trials Testing a new drug Ethical Issues Liability and Indemnity Trial Design Trial Protocol Statistical analysis Clinical Trials Phase I: Phase II: Phase III: Phase
More informationWORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research Involving Human Subjects
WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research Involving Human Subjects Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by
More informationNot All Clinical Trials Are Created Equal Understanding the Different Phases
Not All Clinical Trials Are Created Equal Understanding the Different Phases This chapter will help you understand the differences between the various clinical trial phases and how these differences impact
More informationGENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8 Current
More informationThe Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
More informationGlossary of Clinical Trial Terms
Glossary of Clinical Trial Terms ADVERSE REACTION: (Adverse Event): Also known as side effects, adverse reactions include any undesired actions or effects of the experimental drug or treatment. Experimental
More informationWORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI
WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research Involving Human Subjects Adopted by the 18 th WMA General Assembly Helsinki, Finland, June 1964 and amended by
More informationICH Topic E 8 General Considerations for Clinical Trials. Step 5 NOTE FOR GUIDANCE ON GENERAL CONSIDERATIONS FOR CLINICAL TRIALS (CPMP/ICH/291/95)
European Medicines Agency March 1998 CPMP/ICH/291/95 ICH Topic E 8 General Considerations for Clinical Trials Step 5 NOTE FOR GUIDANCE ON GENERAL CONSIDERATIONS FOR CLINICAL TRIALS (CPMP/ICH/291/95) TRANSMISSION
More informationClinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute
Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,
More informationTGN 1412 Welche Änderungen haben sich für die Erstanwendung am Menschen aus Sicht des BfArM ergeben?
TGN 1412 Welche Änderungen haben sich für die Erstanwendung am Menschen aus Sicht des BfArM ergeben? PD Dr. med. Thomas Sudhop Bundesinstitut für Arzneimittel, Bonn Bundesinstitut für Arzneimittel IMP
More informationNATIONAL HEALTH COUNCIL RESOLUTION Nº 251, DATED 7 AUGUST 1997
NATIONAL HEALTH COUNCIL RESOLUTION Nº 251, DATED 7 AUGUST 1997 Plenary of the National Health Council in its 15 th Special Meeting, held on 5 August 1997, in the exercise of its competencies, as set forth
More informationNONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS
More informationU.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
More informationCLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD
CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationClinical Trials: Questions and Answers
Clinical Trials: Questions and Answers Key Points Clinical trials are research studies that test how well new medical approaches work in people (see Question 1). Every clinical trial has a protocol, which
More informationSession 6 Clinical Trial Assessment Phase I Clinical Trial
L1 Session 6 Clinical Trial Assessment Phase I Clinical Trial Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office
More informationUniversity of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol
University of Hawai i Human Studies Program Guidelines for Developing a Clinical Research Protocol Following are guidelines for writing a clinical research protocol for submission to the University of
More informationGuidance for Industry
Guidance for Industry Codevelopment of Two or More New Investigational Drugs for Use in Combination U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationMedicine Safety Glossary
The following definitions are provided as a resource to supplement the information provided in the Medicine Safety Education section of the Pfizer.com Web site; they are not intended as a comprehensive
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationStatistics and Pharmacokinetics in Clinical Pharmacology Studies
Paper ST03 Statistics and Pharmacokinetics in Clinical Pharmacology Studies ABSTRACT Amy Newlands, GlaxoSmithKline, Greenford UK The aim of this presentation is to show how we use statistics and pharmacokinetics
More information1. Study title Is the title self explanatory to a layperson? If not, a simplified title should be included.
These guidelines apply to all research projects where human subjects are involved in the study GUIDELINES FOR RESEARCHERS PATIENT INFORMATION SHEET & CONSENT FORM The guidance, which follows, applies primarily
More informationCLINICAL TRIALS WITH MEDICINES IN EUROPE
CLINICAL TRIALS WITH MEDICINES IN EUROPE REGULATORY FRAMEWORK FOR CLINICAL TRIALS WITH MEDICINES IN EUROPE The pharmaceutical industry is the most highly regulated sector in Europe. The Commission has
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationAnticancer Drug Clinical Trial Guideline. (version 2.0)
Anticancer Drug Clinical Trial Guideline (version 2.0) May, 2007 1 Table of Contents 1. Introduction... 4 2. The Overall Consideration of Clinical Trial... 4 2.1 The Selection of Patients... 4 2.2 Dose
More informationGuidance for Industry
Guidance for Industry S9 Nonclinical Evaluation for Anticancer Pharmaceuticals U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center
More informationJournal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators
Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University
More informationPharmacology skills for drug discovery. Why is pharmacology important?
skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More informationA Phase 2 Study of Interferon Beta-1a (Avonex ) in Ulcerative Colitis
A Phase 2 Study of (Avonex ) in Ulcerative Colitis - Study Results - ClinicalTrials.gov A Phase 2 Study of (Avonex ) in Ulcerative Colitis This study has been completed. Sponsor: Biogen Idec Information
More informationRESEARCH INVOLVING HUMAN SUBJECTS
RESEARCH INVOLVING HUMAN SUBJECTS GUIDELINES FOR IRBS PART A: INTRODUCTION AND CURRENT FRAMEWORK SECTION I: INTRODUCTION 1. Introduction About these Guidelines 1.1. The Bioethics Advisory Committee (BAC)
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL EVALUATION OF ANTICANCER MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 23 July 1998 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL
More informationNational Cancer Institute
National Cancer Institute Taking Part in Cancer Treatment Research Studies U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Taking Part in Cancer Treatment Research Studies If
More informationEthics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong. Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015
Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015 Clinical Trials at HKU Phase 1 Phase II Phase III Phase IV Conducted on patient
More informationTUTORIAL on ICH E9 and Other Statistical Regulatory Guidance. Session 1: ICH E9 and E10. PSI Conference, May 2011
TUTORIAL on ICH E9 and Other Statistical Regulatory Guidance Session 1: PSI Conference, May 2011 Kerry Gordon, Quintiles 1 E9, and how to locate it 2 ICH E9 Statistical Principles for Clinical Trials (Issued
More informationAdoption by CHMP for release for consultation November 2010. End of consultation (deadline for comments) 31 March 2011
1 2 3 November 2010 EMA/759784/2010 Committee for Medicinal Products for Human Use 4 5 6 7 Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and
More informationProof-of-Concept Studies and the End of Phase IIa Meeting with the FDA
Medpace Discovery Series presents Proof-of-Concept Studies and the End of Phase IIa Meeting with the FDA DR. JIM WEI: Today my topic is going to be Proof-of-Concept Studies and FDA End of Phase 2a Meetings
More informationHollie Goddard Sr. IRB Coordinator McKesson Specialty Health
Hollie Goddard Sr. IRB Coordinator McKesson Specialty Health We are responsible for acquiring, analyzing, and protecting medical information vital to providing quality patient care HIM professionals ensure
More informationAdvancing research: a physician s guide to clinical trials
Advancing research: a physician s guide to clinical trials Recruiting and retaining trial participants is one of the greatest obstacles to developing the next generation of Alzheimer s treatments Alzheimer
More informationTAKING PART IN CANCER TREATMENT RESEARCH STUDIES
For more infomation about Cancer Clinical Trials at Upstate Cancer Center please call Upstate Connect 1.800.464.8668 TAKING PART IN CANCER TREATMENT RESEARCH STUDIES Information provided by: National Cancer
More informationWhat Cancer Patients Need To Know
Taking Part in Clinical Trials What Cancer Patients Need To Know NATIONAL INSTITUTES OF HEALTH National Cancer Institute Generous support for this publication was provided by Novartis Oncology. Taking
More informationSponsor Novartis Pharmaceuticals
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Generic Drug Name Indacaterol Therapeutic Area of Trial Chronic Obstructive Pulmonary Disease (COPD) Indication studied: COPD Study
More informationDefinition of Investigational Medicinal Products (IMPs) Definition of Non Investigational Medicinal Products (NIMPs)
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Definition of Investigational Medicinal Products (IMPs) Definition of Non Investigational Medicinal Products
More informationIssues Regarding Use of Placebo in MS Drug Trials. Peter Scott Chin, MD Novartis Pharmaceuticals Corporation
Issues Regarding Use of Placebo in MS Drug Trials Peter Scott Chin, MD Novartis Pharmaceuticals Corporation Context of the Guidance The draft EMA Guidance mentions placebo as a comparator for superiority
More information4.1 Objectives of Clinical Trial Assessment
L1 4.1 Objectives of Clinical Trial Assessment Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office of Clinical
More informationA responsible approach to clinical trials. Bioethics in action
A responsible approach to clinical trials Bioethics in action What is bioethics? At Novo Nordisk bioethics is the expression used for all ethical issues related to the use of life science technologies
More informationCTC Technology Readiness Levels
CTC Technology Readiness Levels Readiness: Software Development (Adapted from CECOM s Software Technology Readiness Levels) Level 1: Basic principles observed and reported. Lowest level of software readiness.
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE STATISTICAL PRINCIPLES FOR CLINICAL TRIALS E9 Current
More informationClinical Trials and YOU
Clinical Trials and YOU What are clinical trials? Controlled studies to determine how a particular anti-cancer strategy ( i.e. treatment ) affects the people who receive it Involve rigorous scientific
More informationBios 6648: Design & conduct of clinical research
Bios 6648: Design & conduct of clinical research Section 1 - Specifying the study setting and objectives 1. Specifying the study setting and objectives 1.0 Background Where will we end up?: (a) The treatment
More informationEU Clinical Trials Register
EU Clinical Trials Register Disclaimer: The explanations are provided for the benefit of public users of the system and to enhance general understanding of terms used. They are not intended as the regulatory
More informationThe Promise and Challenge of Adaptive Design in Oncology Trials
THE POWER OFx Experts. Experience. Execution. The Promise and Challenge of Adaptive Design in Oncology Trials Clinical oncology trials are more complex and time consuming than those in any other therapeutic
More information2.0 Synopsis. Vicodin CR (ABT-712) M05-765 Clinical Study Report R&D/07/095. (For National Authority Use Only) to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Vicodin CR Name of Active Ingredient: Hydrocodone/Acetaminophen Extended Release (ABT-712) Individual Study Table Referring to Part of Dossier: Volume:
More informationClinical trials in haemophilia
Clinical trials in haemophilia Dr. Paul Giangrande Oxford Haemophilia and Thrombosis Centre & Nuffield Department of Clinical Medicine University of Oxford paul.giangrande@ndm.ox.ac.uk Why do clinical
More informationHumulin (LY041001) Page 1 of 1
(LY041001) These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page Sponsor Novartis Generic Drug Name BGT6 Therapeutic Area of Trial Advanced solid malignancies Approved Indication Investigational Study Number CBGT6A0 Title A phase
More informationICH M3 (R2) Guideline on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
ICH M3 (R2) Guideline on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals International Conference on Harmonisation of Technical Requirements
More informationGuidance Notes for Applicants of the Certificate for Clinical Trial on Medical Device
Guidance Notes for Applicants of the Certificate for Clinical Trial on Medical Device List of Contents Page 1. Introduction 1.1 The Medical Device Administrative Control System and the 3 proposed legislation
More informationIF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN
+ IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN Rena Buckstein MD FRCPC Head Hematology Site Group Sunnybrook Odette Cancer Center (OCC) Head of Hematology Clinical Trials Group at OCC + Outline Start
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationManaging Risk in Clinical Research. Dr Martha J Wrigley R&D Manager Senior Visiting Fellow University of Surrey
Managing Risk in Clinical Research Dr Martha J Wrigley R&D Manager Senior Visiting Fellow University of Surrey Aim of the session To explore the risks associated with clinical research and understand how
More informationOperational aspects of a clinical trial
Operational aspects of a clinical trial Carlo Tomino Pharm.D. Coordinator Pre-authorization Department Head of Research and Clinical Trial Italian Medicines Agency Mwanza (Tanzania), June 11, 2012 1 Declaration
More informationGuidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials
More informationRESEARCH SUBJECT INFORMATION AND CONSENT FORM
1 1 1 1 1 1 1 0 1 0 1 0 RESEARCH SUBJECT INFORMATION AND CONSENT FORM TITLE: PROTOCOL NR: SPONSOR: INVESTIGATOR: WIRB VCU tracking number This template is based on a drug or device research study. The
More informationAdocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro
PRESS RELEASE Adocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro BioChaperone Lispro is significantly faster than Humalog in type I diabetic patients;
More informationGoals & Objectives. Drug Development & the FDA Pharmacy 309. Outline. An History of Disasters. Be able to describe
Drug Development & the FDA Pharmacy 309 Tom Hazlet, Pharm.D., Dr.P.H. 616-2732 thazlet@u... Goals & Objectives Be able to describe the major regulatory events in the drug development process the concepts
More informationOverview of Drug Development: the Regulatory Process
Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Adapted from course taught by Cato Research Background: Roger
More informationKENTUCKY ADMINISTRATIVE REGULATIONS TITLE 201. GENERAL GOVERNMENT CABINET CHAPTER 9. BOARD OF MEDICAL LICENSURE
KENTUCKY ADMINISTRATIVE REGULATIONS TITLE 201. GENERAL GOVERNMENT CABINET CHAPTER 9. BOARD OF MEDICAL LICENSURE 201 KAR 9:260. Professional standards for prescribing and dispensing controlled substances.
More informationClinical Trials at PMH
Clinical Trials at PMH What You Need To Know UHN Patient Education Improving Health Through Education A Guide for Patients, Their Families and Friends in the PMH Cancer Program This information is to be
More informationGuidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products
Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationUpdate and Review of Medication Assisted Treatments
Update and Review of Medication Assisted Treatments for Opiate and Alcohol Use Disorders Richard N. Whitney, MD Medical Director Addiction Services Shepherd Hill Newark, Ohio Medication Assisted Treatment
More information1. Overview of Clinical Trials
1. Overview of Clinical Trials 1.1. What are clinical trials? Definition A clinical trial is a planned experiment which involves patients and is designed to elucidate the most appropriate treatment of
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 18 December 2002 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE
More informationA Peak at PK An Introduction to Pharmacokinetics
Paper IS05 A Peak at PK An Introduction to Pharmacokinetics Hannah Twitchett, Roche Products Ltd, Welwyn Garden City, UK Paul Grimsey, Roche Products Ltd, Welwyn Garden City, UK ABSTRACT The aim of this
More informationA clinical research organization
A clinical research organization About Us State of art facility. All clinical trials carried out in accordance with ICH GCP guidelines. Quality services within stipulated time period. Team of experienced
More informationA Guide to Clinical Trials
A Guide to Clinical Trials For young people with cancer and their parents Children s Cancer and Leukaemia Group www.cclg.org.uk Original booklet produced in conjunction with the CCLG Patient Advocacy Committee.
More informationGuidance for Industry
Guidance for Industry E9 Statistical Principles for Clinical Trials U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE E15
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE DEFINITIONS FOR GENOMIC BIOMARKERS, PHARMACOGENOMICS,
More informationICH CRA Certification Guide March 2009
ICH CRA Certification Guide March 2009 ICH CRA CERTIFICATION GUIDE... 1 GENERAL INFORMATION... 2 BENEFITS OF CERTIFICATION... 2 INDUSTRY RECOGNITION... 2 ABOUT THE EXAM... 2 CRA DEFINITION... 2 REQUIREMENTS
More informationSubject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure
703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a
More informationNursing 113. Pharmacology Principles
Nursing 113 Pharmacology Principles 1. The study of how drugs enter the body, reach the site of action, and are removed from the body is called a. pharmacotherapeutics b. pharmacology c. pharmacodynamics
More informationNational MS Society Information Sourcebook www.nationalmssociety.org/sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Chemotherapy The literal meaning of the term chemotherapy is to treat with a chemical agent, but the term generally refers
More informationEffective Outsourcing of Clinical Pharmacology Studies in Europe. John Horkulak Executive Director, Eurasian External Clinical Study Operations
Effective Outsourcing of Clinical Pharmacology Studies in Europe John Horkulak Executive Director, Eurasian External Clinical Study Operations Key Questions Do clinical pharmacology studies require a different
More informationFrequently Asked Questions (FAQs)
Frequently Asked Questions (FAQs) Research Rationale 1. What does PrEP stand for? There is scientific evidence that antiretroviral (anti-hiv) medications may be able to play an important role in reducing
More informationConduct of clinical Trials Communication of
PrinciPles on Conduct of clinical Trials Communication of clinical Trial results Table of Contents Preamble...1 Commitment to Protecting Research Participants...5 Conduct of Clinical Trials...7 Ensuring
More informationThe Australian Clinical Trial Handbook
The Australian Clinical Trial Handbook A simple, practical guide to the conduct of clinical trials to International standards of Good Clinical Practice (GCP) in the Australian context About the Therapeutic
More informationBackground Definition Why do we need it? The process of obtaining informed consent A brief overview of special situations Conclusion
Joanna Forbes Senior Clinical Research Nurse Ethical and legal considerations Background Definition Why do we need it? The process of obtaining informed consent A brief overview of special situations Conclusion
More informationGuidance for Industry
Guidance for Industry End-of-Phase 2A Meetings U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 Procedural Guidance
More informationCourse Curriculum for Master Degree in Clinical Pharmacy
Course Curriculum for Master Degree in Clinical Pharmacy The Master Degree in Clinical Pharmacy is awarded by the Faculty of Graduate studies at Jordan University of Science and Technology (JUST) upon
More informationClinical research: where are we with the new (Paediatric) RC trial Regulation
where are we with the new (Paediatric) RC trial Regulation, MD, PhD Ethical Committee DEEP Former member of the PDCO EMA With the aid of Fabio D'Atri European commission and Anabela Marcal of EMA The new
More informationBIOAVAILABILITY & BIOEQUIVALENCE TRIALS
BIOAVAILABILITY & BIOEQUIVALENCE TRIALS Shubha Rani,, Ph.D. Technical Director & Head-Biometrics and Data Management Synchron Research Services Pvt. Ltd. Ahmedabad 380 054 drshubha@synchronresearch.com
More informationTest Content Outline Effective Date: June 9, 2014. Pain Management Nursing Board Certification Examination
Pain Management Nursing Board Certification Examination There are 175 questions on this examination. Of these, 150 are scored questions and 25 are pretest questions that are not scored. Pretest questions
More informationRegulatory Issues in Genetic Testing and Targeted Drug Development
Regulatory Issues in Genetic Testing and Targeted Drug Development Janet Woodcock, M.D. Deputy Commissioner for Operations Food and Drug Administration October 12, 2006 Genetic and Genomic Tests are Types
More informationHow To Choose A Biologic Drug
North Carolina Rheumatology Association Position Statements I. Biologic Agents A. Appropriate delivery, handling, storage and administration of biologic agents B. Indications for biologic agents II. III.
More informationNon-clinical development of biologics
Aurigon Life Science GmbH Non-clinical development of biologics Requirements, challenges and case studies Committed to Life. Sigrid Messemer vet. med. M4 Seminar March 10 th 2014 Aurigon - your full service
More informationCLINICAL TRIALS: Part 2 of 2
CLINICAL TRIALS: Part 2 of 2 Lance K. Heilbrun, Ph.D., M.P.H. Professor of Medicine and Oncology Division of Hematology and Oncology Wayne State University School of Medicine Assistant Director, Biostatistics
More informationNewsletter. WntResearch AB, Medeon Science Park, Per Albin Hanssons väg 41, 205 12 Malmö, Sweden. Primary Objective:
Newsletter This resume of the results from the phase 1 study with Foxy-5 is based on clinical and laboratory data from the study, and these data have now been locked into the database. The full report
More informationEfficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics
Efficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics This trial is conducted in the United States of America (USA). The aim of this clinical
More information